Scarica l'app Stockscreener
4.9098
30.51%
0.9498
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.96
Aprire:
$4.49
Volume 24 ore:
473.32K
Relative Volume:
5.39
Capitalizzazione di mercato:
$258.24M
Reddito:
$3.50M
Utile/perdita netta:
$-80.40M
Rapporto P/E:
-1.9096
EPS:
-2.5711
Flusso di cassa netto:
$-29.83M
1 W Prestazione:
+28.89%
1M Prestazione:
+19.91%
6M Prestazione:
-26.27%
1 anno Prestazione:
+256.43%
Intervallo 1D:
$4.42
$5.25
Intervallo di 1 settimana:
$3.95
$5.24
Portata 52W:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
617-651-8867
Indirizzo
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.9733 | 205.63M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
446.42 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.25 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
871.67 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.78 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.75 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Rodman & Renshaw | Buy |
| 2025-10-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Iniziato | Wedbush | Outperform |
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | William Blair | Outperform |
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan - TipRanks
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) grants director 28,000 stock options - Stock Titan
Camp4 Therapeutics (CAMP) director granted options on 28,000 shares at $4.34 - Stock Titan
Camp4 Therapeutics director granted 28,000 options | CAMP Insider Trading - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike - Stock Titan
Camp4 Therapeutics director granted 28K options | CAMP Insider Trading - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) updates equity plans and elects Class II directors - Stock Titan
CAMP Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
Chardan initiates CAMP4 Therapeutics stock with buy rating - Investing.com UK
Chardan initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Canada
CAMP4 Therapeutics Q1 2026 Earnings: EPS Misses Estimates by 49.4% as Pre-Revenue Biotech Faces R&D Cost PressureEPS Estimate Trend - newsline.com
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Yahoo Finance
CAMP4 Therapeutics (CAMP) Holds Gains: Approaching Key Resistance at $4.47Bearish Pattern Stocks - newsline.com
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP4 Therapeutics (CAMP) Edges Higher Amid Continued VolatilityRisk Reward Setups - The Legal Advocate
CAMP4 Therapeutics Surges 4.5% as Biotech Sentiment Improves — CAMP Tests Key ResistanceMomentum Stock Picks - newsline.com
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Pressures Sentiment, but Stock Holds SteadyProduct Revenue Analysis - The Legal Advocate
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy - Traders Union
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model - BioWorld News
Balyasny Asset Management (CAMP) reports 2.63M shares; 4.99% warrant blocker - Stock Titan
CAMP4 Therapeutics Reports Preclinical Success of CMP-002 in Reducing Seizures for SYNGAP1-Related Disorder, Plans Phase 1/2 Trial in 2026 - Minichart
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy - TipRanks
CAMP4 reports positive preclinical seizure data for CMP-002 - Investing.com
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston - Traders Union
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - The Manila Times
CAMP4 Therapeutics to Present New Preclinical Data - GlobeNewswire
Camp4 Therapeutics Corp targets capital discipline with new R and D focus - Traders Union
CAMP4 Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments - Traders Union
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Rare-disease drug moves toward human trial as CAMP4 projects cash into 2028 - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) details Q1 2026 results and cash runway into 2028 - Stock Titan
Camp4 Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1% - MarketBeat
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Camp 4 Therapeutics Corp Azioni (CAMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):